Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030193 (
pain
)
261,466
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In an open study, thirty-five patients with active rheumatoid arthritis were treated with phenytoin. Various clinical and laboratory parameters showed good improvement after phenytoin.
Early morning stiffness
was significantly reduced after 8 weeks (p less than 0.05);
pain
index (p less than 0.001), articular index (p less than 0.01) and grip strength (p less than 0.01) showed significant improvement after 24 weeks. There was significant reduction in erythrocyte sedimentation rate (p less than 0.01). Except for three patients (skin rash in one and gastric irritation in two), all others tolerated phenytoin well. The results of the present study support the usefulness of phenytoin as a disease-modifying drug for rheumatoid arthritis.
...
PMID:Evaluation of phenytoin in rheumatoid arthritis--an open study. 175 90
A trial was designed to assess the effects of intramuscular sodium aurothiomalate or intravenous cyclophosphamide, or both, in combination with intravenous 'pulse' methylprednisolone in severe intractable rheumatoid arthritis. Thirteen patients with severe, active rheumatoid arthritis, unresponsive to conventional therapeutic regimens showed improvement in synovitis after receiving a single intravenous bolus of methylprednisolone (15 mg/kg).
Early morning stiffness
and Ritchie articular index remained improved over pretreatment values after 12 weeks. There was an early fall in the erythrocyte sedimentation rate, which returned to baseline levels by four weeks. A concomitant intravenous pulse of cyclophosphamide (1 g/m2 body surface area) given to eight patients did not confer any additional benefit. Six patients received sodium aurothiomalate, up to 100 mg intramuscularly a week, and in these patients the early improvement in synovitis induced by methylprednisolone was maintained. Thus between 12 and 24 weeks the Ritchie articular index, visual analogue
pain
score, erythrocyte sedimentation rate, haemoglobin, and immunoglobin G were significantly better in the patients treated with gold and methylprednisolone than in those treated with methylprednisolone alone, irrespective of whether they had received cyclophosphamide. Methylprednisolone pulse therapy given at the start of gold treatment results in early improvement in synovitis, maintained until the usual delay in achieving a therapeutic effect from gold has elapsed.
...
PMID:Combined suppressive drug treatment in severe refractory rheumatoid disease: an analysis of the relative effects of parenteral methylprednisolone, cyclophosphamide, and sodium aurothiomalate. 314 41